New-onset diabetes after transplantation: Risk factors and clinical impact;Diabète de novo post-greffe: facteurs de risque et conséquences cliniques

Diabetes and Metabolism

Volumn 37, Issue 1, 2011, Pages 1-14

  Rakel A ^a   Karelis, A D ^b,c  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^c CENTRE DE RECHERCHE   (Canada)

Author keywords

Corticosteroids; Cyclosporin; Post transplant diabetes mellitus; Review; Tacrolimus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; EXENDIN 4; INSULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; TACROLIMUS;

AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE; BODY WEIGHT; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIABETOGENESIS; DIAGNOSTIC TEST; DISEASE ASSOCIATION; ETHNIC DIFFERENCE; GLUCOSE TOLERANCE; GRAFT FAILURE; GRAFT REJECTION; GROUPS BY AGE; HEART TRANSPLANTATION; HEPATITIS C; HEREDITY; HUMAN; HYPERGLYCEMIA; HYPOMAGNESEMIA; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY GRAFT; KIDNEY POLYCYSTIC DISEASE; LIFESTYLE MODIFICATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MORTALITY; NEW ONSET DIABETES AFTER TRANSPLANTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; POPULATION RESEARCH; REVIEW; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE;

EID: 79951770247     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2010.09.003     Document Type: Review

References (157)

1. Starzl T.E., Marchioro T.L., Rifkind D., Holmes J.H., Rowlands D.T., Waddell W.R. Factors in successful renal transplantation. Surgery 1964, 56:296-318.
2. Kasiske B.L., Snyder J.J., Gilbertson D., Matas A.J. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003, 3:178-185.
3. Davidson J., Wilkinson A., Dantal J., Dotta F., Haller H., Hernandez D., et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Transplantation 2003, 75:SS3-SS24.
4. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2008; 31(Suppl. 1):S55-60.
5. Shaw J.E., Zimmet P.Z., Alberti K.G.M.M. Point: impaired fasting glucose: the case for the New American Diabetes Association Criterion. Diabetes Care 2006, 29:1170-1172.
6. Bloom R.D., Crutchlow M.F. Transplant-associated hyperglycemia. Transplant Rev (Orlando) 2008, 22:39-51.
7. Montori V.M., Basu A., Erwin P.J., Velosa J.A., Gabriel S.E., Kudva Y.C. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care 2002, 25:583-592.
8. Woodward R.S., Schnitzler M.A., Baty J., Lowell J.A., Lopez-Rocafort L., Haider S., et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 2003, 3:590-598.
9. Cosio F.G., Kudva Y., van der Velde M., Larson T.S., Textor S.C., Griffin M.D., et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 2005, 67:2415-2421.
10. Nam J.H., Mun J.I., Kim S.I., Kang S.W., Choi K.H., Park K., et al. Beta-Cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitus. Transplantation 2001, 71:1417-1423.
11. Luan FL, Stuckey LJ, Ojo AO. Abnormal glucose metabolism and metabolic syndrome in non-diabetic kidney transplant recipients early after transplantation. Transplantation 2010;89:1034-9.
12. Cosio F.G., Pesavento T.E., Osei K., Henry M.L., Ferguson R.M. Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int 2001, 59:732-737.
13. Heisel O., Heisel R., Balshaw R., Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 2004, 4:583-595.
14. Baid S., Cosimi A.B., Farrell M.L., Schoenfeld D.A., Feng S., Chung R.T., et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 2001, 72:1066-1072.
15. Khalili M., Lim J.W., Bass N., Ascher N.L., Roberts J.P., Terrault N.A. New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection. Liver Transpl 2004, 10:349-355.
16. Valderhaug T.G., Hjelmesaeth J., Rollag H., Leivestad T., Roislien J., Jenssen T., et al. Reduced incidence of new-onset posttransplantation diabetes mellitus during the last decade. Transplantation 2007, 84:1125-1130.
17. Ye X, Kuo HT, Sampaio MS, Jiang Y, Reddy P, Bunnapradist S. Risk factors for development of new-onset diabetes mellitus in adult heart transplant recipients. Transplantation 2010;89:1526-32.
18. Silverborn M., Jeppsson A., Martensson G., Nilsson F. New-onset cardiovascular risk factors in lung transplant recipients. J Heart Lung Transplant 2005, 24:1536-1543.
19. Sumrani N.B., Delaney V., Ding Z.K., Davis R., Daskalakis P., Friedman E.A., et al. Diabetes mellitus after renal transplantation in the cyclosporine era - an analysis of risk factors. Transplantation 1991, 51:343-347.
20. Armstrong K.A., Campbell S.B., Hawley C.M., Nicol D.L., Johnson D.W., Isbel N.M. Obesity is associated with worsening cardiovascular risk factor profiles and proteinuria progression in renal transplant recipients. Am J Transplant 2005, 5:2710-2718.
21. Williams J.J., Lund L.H., LaManca J., Kunavarapu C., Cohen D.J., Heshka S., et al. Excessive weight gain in cardiac transplant recipients. J Heart Lung Transplant 2006, 25:36-41.
22. Johnson C.P., Gallagher-Lepak S., Zhu Y.R., Porth C., Kelber S., Roza A.M., et al. Factors influencing weight gain after renal transplantation. Transplantation 1993, 56:822-827.
23. Richards J., Gunson B., Johnson J., Neuberger J. Weight gain and obesity after liver transplantation. Transpl Int 2005, 18:461-466.
24. Marrero D, Hernandez D, Tamajon LP, Rivero M, Lampreabe I, Checa MD, et al. Pre-transplant weight but not weight gain is associated with new-onset diabetes after transplantation: a multi-centre cohort Spanish study. NDT Plus 2010;3:ii15-20.
25. Ducloux D., Motte G., Vautrin P., Bresson-Vautrin C., Rebibou J.M., Chalopin J.M. Polycystic kidney disease as a risk factor for post-transplant diabetes mellitus. Nephrol Dial Transplant 1999, 14:1244-1246.
26. de Mattos A.M., Olyaei A.J., Prather J.C., Golconda M.S., Barry J.M., Norman D.J. Autosomal-dominant polycystic kidney disease as a risk factor for diabetes mellitus following renal transplantation. Kidney Int 2005, 67:714-720.
27. Hamer R.A., Chow C.L., Ong A.C., McKane W.S. Polycystic kidney disease is a risk factor for new-onset diabetes after transplantation. Transplantation 2007, 83:36-40.
28. Vareesangthip K., Tong P., Wilkinson R., Thomas T.H. Insulin resistance in adult polycystic kidney disease. Kidney Int 1997, 52:503-508.
29. Sumrani N., Delaney V., Ding Z., Davis R., Daskalakis P., Friedman E.A., et al. Posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplant Proc 1991, 23:1249-1250.
30. Chakkera H.A., Hanson R.L., Raza S.M., DiStefano J.K., Millis M.P., Heilman R.L., et al. Pilot study: association of traditional and genetic risk factors and new-onset diabetes mellitus following kidney transplantation. Transplant Proc 2009, 41:4172-4177.
31. Kang E.S., Kim M.S., Kim Y.S., Hur K.Y., Han S.J., Nam C.M., et al. A variant of the transcription factor 7-like 2 (TCF7L2) gene and the risk of posttransplantation diabetes mellitus in renal allograft recipients. Diabetes Care 2008, 31:63-68.
32. Kang E.S., Kim M.S., Kim Y.S., Kim C.H., Han S.J., Chun S.W., et al. A polymorphism in the zinc transporter gene SLC30A8 confers resistance against posttransplantation diabetes mellitus in renal allograft recipients. Diabetes 2008, 57:1043-1047.
33. Chausmer A.B. Zinc, insulin and diabetes. J Am Coll Nutr 1998, 17:109-115.
34. Sladek R., Rocheleau G., Rung J., Dina C., Shen L., Serre D., et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007, 445:881-885.
35. Scott L.J., Mohlke K.L., Bonnycastle L.L., Willer C.J., Li Y., Duren W.L., et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007, 316:1341-1345.
36. Grant S.F., Thorleifsson G., Reynisdottir I., Benediktsson R., Manolescu A., Sainz J., et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006, 38:320-323.
37. Florez J.C., Jablonski K.A., Bayley N., Pollin T.I., de Bakker P.I., Shuldiner A.R., et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 2006, 355:241-250.
38. Groves C.J., Zeggini E., Minton J., Frayling T.M., Weedon M.N., Rayner N.W., et al. Association analysis of 6,736 U.K. subjects provides replication and confirms TCF7L2 as a type 2 diabetes susceptibility gene with a substantial effect on individual risk. Diabetes 2006, 55:2640-2644.
39. Vozarova B., Fernandez-Real J.M., Knowler W.C., Gallart L., Hanson R.L., Gruber J.D., et al. The interleukin-6 (-174) G/C promoter polymorphism is associated with type-2 diabetes mellitus in Native Americans and Caucasians. Hum Genet 2003, 112:409-413.
40. Bamoulid J., Courivaud C., Deschamps M., Mercier P., Ferrand C., Penfornis A., et al. IL-6 promoter polymorphism -174 is associated with new-onset diabetes after transplantation. J Am Soc Nephrol 2006, 17:2333-2340.
41. Kurzawski M, Dziewanowski K, Kedzierska K, Gornik W, Banas A, Drozdzik M. Association of calpain-10 gene polymorphism and posttransplant diabetes mellitus in kidney transplant patients medicated with tacrolimus. Pharmacogenomics J 2010;10:120-5.
42. Mehta S.H., Brancati F.L., Sulkowski M.S., Strathdee S.A., Szklo M., Thomas D.L. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000, 133:592-599.
43. Ozyilkan E., Erbas T., Simsek H., Telatar F., Kayhan B., Telatar H. Increased prevalence of hepatitis C virus antibodies in patients with diabetes mellitus. J Intern Med 1994, 235:283-284.
44. Bloom R.D., Rao V., Weng F., Grossman R.A., Cohen D., Mange K.C. Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol 2002, 13:1374-1380.
45. Fabrizi F., Martin P., Dixit V., Bunnapradist S., Kanwal F., Dulai G. Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies. Am J Transplant 2005, 5:2433-2440.
46. Delgado-Borrego A., Casson D., Schoenfeld D., Somsouk M., Terella A., Jordan S.H., et al. Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation. Transplantation 2004, 77:703-710.
47. Kamar N., Toupance O., Buchler M., Sandres-Saune K., Izopet J., Durand D., et al. Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol 2003, 14:2092-2098.
48. Arase Y., Suzuki F., Suzuki Y., Akuta N., Kobayashi M., Kawamura Y., et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 2009, 49:739-744.
49. Hjelmesæth J., Sagedal S., Hartmann A., Rollag H., Egeland T., Hagen M., et al. Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia 2004, 47:1550-1556.
50. Driscoll C.J., Cashion A.K., Hathaway D.K., Thompson C., Conley Y., Gaber O., et al. Posttransplant diabetes mellitus in liver transplant recipients. Prog Transplant 2006, 16:110-116.
51. Hjelmesaeth J., Muller F., Jenssen T., Rollag H., Sagedal S., Hartmann A. Is there a link between cytomegalovirus infection and new-onset posttransplantation diabetes mellitus? Potential mechanisms of virus induced beta-cell damage. Nephrol Dial Transplant 2005, 20:2311-2315.
52. Ki E.L.L., Venetz J.-P., Meylan P., Lamoth F., Ruiz J., Pascual M. Cytomegalovirus infection and new-onset post-transplant diabetes mellitus. Clin Transplant 2008, 22:245-249.
53. Hirsch I.B., Paauw D.S. Diabetes management in special situations. Endocrinol Metab Clin North Am 1997, 26:631-645.
54. Hjelmesaeth J., Hartmann A., Kofstad J., Stenstrom J., Leivestad T., Egeland T., et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997, 64:979-983.
55. Gunnarsson R., Arner P., Lundgren G., Magnusson G., Ostman J., Groth C.G. Diabetes mellitus - a more-common-than-believed complication of renal transplantation. Transplant Proc 1979, 11:1280-1281.
56. Weir M.R., Fink J.C. Risk for post-transplant Diabetes mellitus with current immunosuppressive medications. Am J Kidney Dis 1999, 34:1-13.
57. Hjelmesaeth J., Hartmann A., Kofstad J., Egeland T., Stenstrom J., Fauchald P. Tapering off prednisolone and cyclosporin the first year after renal transplantation: the effect on glucose tolerance. Nephrol Dial Transplant 2001, 16:829-835.
58. Hricik D.E., Bartucci M.R., Moir E.J., Mayes J.T., Schulak J.A. Effects of steroid withdrawal on post-transplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplantation 1991, 51:374-377.
59. Hollander A.A., Hene R.J., Hermans J., van Es L.A., van der Woude F.J. Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: a randomized study. J Am Soc Nephrol 1997, 8:294-301.
60. Woodle E.S., First M.R., Pirsch J., Shihab F., Gaber A.O., Van Veldhuisen P. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008, 248:564-577.
61. Vincenti F., Schena F.P., Paraskevas S., Hauser I.A., Walker R.G., Grinyo J. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008, 8:307-316.
62. Rostaing L., Cantarovich D., Mourad G., Budde K., Rigotti P., Mariat C., et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 2005, 79:807-814.
63. Midtvedt K., Hjelmesaeth J., Hartmann A., Lund K., Paulsen D., Egeland T., et al. Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal. J Am Soc Nephrol 2004, 15:3233-3239.
64. Vesco L., Busson M., Bedrossian J., Bitker M.O., Hiesse C., Lang P. Diabetes mellitus after renal transplantation: characteristics, outcome, and risk factors. Transplantation 1996, 61:1475-1478.
65. Hahn H.J., Dunger A., Laube F., Besch W., Radloff E., Kauert C., et al. Reversibility of the acute toxic effect of cyclosporin A on pancreatic B cells of Wistar rats. Diabetologia 1986, 29:489-494.
66. Hahn H.J., Laube F., Lucke S., Kloting I., Kohnert K.D., Warzock R. Toxic effects of cyclosporine on the endocrine pancreas of Wistar rats. Transplantation 1986, 41:44-47.
67. Yagisawa T., Takahashi K., Teraoka S., Toma H., Agishi T., Ota K. Effects of cyclosporine on glucose metabolism in kidney transplant recipients and rats. Transplant Proc 1987, 19:1801-1803.
68. Garvin P.J., Niehoff M., Staggenborg J. Cyclosporine's effect on canine pancreatic endocrine function. Transplantation 1988, 45:1027-1031.
69. Nielsen J.H., Mandrup-Poulsen T., Nerup J. Direct effects of cyclosporin A on human pancreatic beta-cells. Diabetes 1986, 35:1049-1052.
70. Yale J.F., Chamelian M., Courchesne S., Vigeant C. Peripheral insulin resistance and decreased insulin secretion after cyclosporine A treatment. Transplant Proc 1988, 20:985-988.
71. Ost L., Tyden G., Fehrman I. Impaired glucose tolerance in cyclosporine-prednisolone-treated renal graft recipients. Transplantation 1988, 46:370-372.
72. Strasser S., Alejandro R., Shapiro E.T., Ricordi C., Todo S., Mintz D.H. Effect of FK506 on insulin secretion in normal dogs. Metabolism 1992, 41:64-67.
73. Hirano Y., Fujihira S., Ohara K., Katsuki S., Noguchi H. Morphological and functional changes of islets of Langerhans in FK506-treated rats. Transplantation 1992, 53:889-894.
74. Tamura K., Fujimura T., Tsutsumi T., Nakamura K., Ogawa T., Atumaru C., et al. Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell. Transplantation 1995, 59:1606-1613.
75. Krentz A.J., Dousset B., Mayer D., McMaster P., Buckels J., Cramb R., et al. Metabolic effects of cyclosporin A and FK 506 in liver transplant recipients. Diabetes 1993, 42:1753-1759.
76. van Hooff J.P., Christiaans M.H., van Duijnhoven E.M. Tacrolimus and posttransplant diabetes mellitus in renal transplantation. Transplantation 2005, 79:1465-1469.
77. Pirsch J.D., Miller J., Deierhoi M.H., Vincenti F., Filo R.S. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997, 63:977-983.
78. Vincenti F., Friman S., Scheuermann E., Rostaing L., Jenssen T., Campistol J.M., et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007, 7:1506-1514.
79. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group. Lancet 1994;344:423-8.
80. Grimm M., Rinaldi M., Yonan N.A., Arpesella G., Arizon Del Prado J.M., Pulpon L.A., et al. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients - a large European trial. Am J Transplant 2006, 6:1387-1397.
81. Vannini S.D., Mazzola B.L., Rodoni L., Truttmann A.C., Wermuth B., Bianchetti M.G., et al. Permanently reduced plasma ionized magnesium among renal transplant recipients on cyclosporine. Transpl Int 1999, 12:244-249.
82. Nadler J.L., Buchanan T., Natarajan R., Antonipillai I., Bergman R., Rude R. Magnesium deficiency produces insulin resistance and increased thromboxane synthesis. Hypertension 1993, 21:1024-1029.
83. Guerrero-Romero F., Tamez-Perez H.E., Gonzalez-Gonzalez G., Salinas-Martinez A.M., Montes-Villarreal J., Trevino-Ortiz J.H., et al. Oral magnesium supplementation improves insulin sensitivity in non-diabetic subjects with insulin resistance. A double-blind placebo-controlled randomized trial. Diabetes Metab 2004, 30:253-258.
84. He K., Song Y., Belin R.J., Chen Y. Magnesium intake and the metabolic syndrome: epidemiologic evidence to date. J Cardiometab Syndr 2006, 1:351-355.
85. Lopez-Ridaura R., Willett W.C., Rimm E.B., Liu S., Stampfer M.J., Manson J.E., et al. Magnesium intake and risk of type 2 diabetes in men and women. Diabetes Care 2004, 27:134-140.
86. Rodriguez-Moran M., Guerrero-Romero F. Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: a randomized double-blind controlled trial. Diabetes Care 2003, 26:1147-1152.
87. Song Y., He K., Levitan E.B., Manson J.E., Liu S. Effects of oral magnesium supplementation on glycaemic control in Type 2 diabetes: a meta-analysis of randomized double-blind controlled trials. Diabet Med 2006, 23:1050-1056.
88. Song Y., Manson J.E., Buring J.E., Liu S. Dietary magnesium intake in relation to plasma insulin levels and risk of type 2 diabetes in women. Diabetes Care 2004, 27:59-65.
89. Van Laecke S., Van Biesen W., Verbeke F., De Bacquer D., Peeters P., Vanholder R. Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation. Am J Transplant 2009, 9:2140-2149.
90. Johnston O., Rose C.L., Webster A.C., Gill J.S. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008, 19:1411-1418.
91. Teutonico A., Schena P.F., Di Paolo S. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 2005, 16:3128-3135.
92. Romagnoli J., Citterio F., Nanni G., Favi E., Tondolo V., Spagnoletti G., et al. Incidence of posttransplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine. Transplant Proc 2006, 38:1034-1036.
93. Gonwa T.A., Hricik D.E., Brinker K., Grinyo J.M., Schena F.P. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 2002, 74:1560-1567.
94. Kahan B.D. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000, 356:194-202.
95. Mendez R., Gonwa T., Yang H.C., Weinstein S., Jensik S., Steinberg S. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. Transplantation 2005, 80:303-309.
96. Syed N.A., Khandelwal R.L. Reciprocal regulation of glycogen phosphorylase and glycogen synthase by insulin involving phosphatidylinositol-3 kinase and protein phosphatase-1 in HepG2 cells. Mol Cell Biochem 2000, 211:123-136.
97. Kwon G., Marshall C.A., Liu H., Pappan K.L., Remedi M.S., McDaniel M.L. Glucose-stimulated DNA synthesis through mammalian target of rapamycin (mTOR) is regulated by KATP channels: effects on cell cycle progression in rodent islets. J Biol Chem 2006, 281:3261-3267.
98. Bussiere C.T., Lakey J.R., Shapiro A.M., Korbutt G.S. The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells. Diabetologia 2006, 49:2341-2349.
99. Kwon G., Marshall C.A., Pappan K.L., Remedi M.S., McDaniel M.L. Signaling elements involved in the metabolic regulation of mTOR by nutrients, incretins, and growth factors in islets. Diabetes 2004, 53(Suppl. 3):S225-S232.
100. First M.R., Gerber D.A., Hariharan S., Kaufman D.B., Shapiro R. Posttransplant diabetes mellitus in kidney allograft recipients: incidence, risk factors, and management. Transplantation 2002, 73:379-386.
101. Aasebo W, Midtvedt K, Valderhaug TG, Leivestad T, Hartmann A, Reisaeter AV, et al. Impaired glucose homeostasis in renal transplant recipients receiving basiliximab. Nephrol Dial Transplant 2010;25:1289-93.
102. Bayes B., Pastor M.C., Lauzurica R., Granada M.L., Salinas I., Romero R. Do anti-CD25 monoclonal antibodies potentiate posttransplant diabetes mellitus?. Transplant Proc 2007, 39:2248-2250.
103. Setoguchi R., Hori S., Takahashi T., Sakaguchi S. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 2005, 201:723-735.
104. Grundy S.M., Benjamin I.J., Burke G.L., Chait A., Eckel R.H., Howard B.V., et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999, 100:1134-1146.
105. Selvin E., Marinopoulos S., Berkenblit G., Rami T., Brancati F.L., Powe N.R., et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004, 141:421-431.
106. O'Brien T., Nguyen T.T., Zimmerman B.R. Hyperlipidemia and diabetes mellitus. Mayo Clin Proc 1998, 73:969-976.
107. Adler A.I., Stratton I.M., Neil H.A., Yudkin J.S., Matthews D.R., Cull C.A., et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000, 321:412-419.
108. Ginsberg H.N. Insulin resistance and cardiovascular disease. J Clin Invest 2000, 106:453-458.
109. Ford E.S. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005, 28:1769-1778.
110. Cosio F.G., Pesavento T.E., Kim S., Osei K., Henry M., Ferguson R.M. Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int 2002, 62:1440-1446.
111. Revanur V.K., Jardine A.G., Kingsmore D.B., Jaques B.C., Hamilton D.H., Jindal R.M. Influence of diabetes mellitus on patient and graft survival in recipients of kidney transplantation. Clin Transplant 2001, 15:89-94.
112. Matas A.J., Humar A., Gillingham K.J., Payne W.D., Gruessner R.W.G., Kandaswamy R., et al. Five preventable causes of kidney graft loss in the 1990s: a single-center analysis 1. Kidney Int 2002, 62:704-714.
113. Ducloux D., Kazory A., Chalopin J.M. Posttransplant diabetes mellitus and atherosclerotic events in renal transplant recipients: a prospective study. Transplantation 2005, 79:438-443.
114. Lentine K.L., Brennan D.C., Schnitzler M.A. Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol 2005, 16:496-506.
115. Meier-Kriesche H.U., Baliga R., Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003, 75:1291-1295.
116. Hjelmesaeth J., Hartmann A., Leivestad T., Holdaas H., Sagedal S., Olstad M., et al. The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int 2006, 69:588-595.
117. Roth D., Milgrom M., Esquenazi V., Fuller L., Burke G., Miller J. Posttransplant hyperglycemia. Increased incidence in cyclosporine-treated renal allograft recipients. Transplantation 1989, 47:278-281.
118. Miles A.M., Sumrani N., Horowitz R., Homel P., Maursky V., Markell M.S., et al. Diabetes mellitus after renal transplantation: as deleterious as non-transplant-associated diabetes?. Transplantation 1998, 65:380-384.
119. Cole E.H., Johnston O., Rose C.L., Gill J.S. Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. Clin J Am Soc Nephrol 2008, 3:814-821.
120. Matas A.J., Gillingham K.J., Humar A., Ibrahim H.N., Payne W.D., Gruessner R.W., et al. Posttransplant diabetes mellitus and acute rejection: impact on kidney transplant outcome. Transplantation 2008, 85:338-343.
121. John P.R., Thuluvath P.J. Outcome of patients with new-onset diabetes mellitus after liver transplantation compared with those without diabetes mellitus. Liver Transpl 2002, 8:708-713.
122. Gane E.J., Portmann B.C., Naoumov N.V., Smith H.M., Underhill J.A., Donaldson P.T., et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996, 334:815-820.
123. Foxton M.R., Quaglia A., Muiesan P., Heneghan M.A., Portmann B., Norris S., et al. The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C. Am J Transpl 2006, 6:1922-1929.
124. Veldt B.J., Poterucha J.J., Watt K.D., Wiesner R.H., Hay J.E., Rosen C.B., et al. Insulin resistance serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. Am J Transplant 2009.
125. Trulock E.P., Edwards L.B., Taylor D.O., Boucek M.M., Keck B.M., Hertz M.I. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult lung and heart-lung transplant report - 2005. J Heart Lung Transplant 2005, 24:956-967.
126. Valantine H., Rickenbacker P., Kemna M., Hunt S., Chen Y.D., Reaven G., et al. Metabolic abnormalities characteristic of dysmetabolic syndrome predict the development of transplant coronary artery disease: a prospective study. Circulation 2001, 103:2144-2152.
127. Bedanova H., Ondrasek J., Cerny J., Orban M., Spinarova L., Hude P., et al. Impact of diabetes mellitus on survival rates after heart transplantation. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2009, 153:283-287.
128. Ramesh Prasad G.V., Huang M., Bandukwala F., Nash M.M., Rapi L., Montada-Atin T., et al. Pre-transplantation glucose testing for predicting new-onset diabetes mellitus after renal transplantation. Clin Nephrol 2009, 71:140-146.
129. Joss N., Staatz C.E., Thomson A.H., Jardine A.G. Predictors of new onset diabetes after renal transplantation. Clin Transplant 2007, 21:136-143.
130. Iida S., Ishida H., Tokumoto T., Omoto K., Shirakawa H., Shimizu T., et al. New-onset diabetes after transplantation in tacrolimus-treated, living kidney transplantation: long-term impact and utility of the pre-transplant OGTT. Int Urol Nephrol 2010, [E-pub ahead of print].
131. Tominaga M., Eguchi H., Manaka H., Igarashi K., Kato T., Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999, 22:920-924.
132. Wilkinson A., Davidson J., Dotta F., Home P.D., Keown P., Kiberd B., et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant 2005, 19:291-298.
133. KDIGO Transplant work group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009;9(Suppl. 3):S1-155.
134. Valderhaug T.G., Jenssen T., Hartmann A., Midtvedt K., Holdaas H., Reisaeter A.V., et al. Fasting plasma glucose and glycosylated hemoglobin in the screening for diabetes mellitus after renal transplantation. Transplantation 2009, 88:429-434.
135. Davidson J.A., Wilkinson A. New-onset diabetes after transplantation 2003 International Consensus Guidelines: an endocrinologist's view. Diabetes Care 2004, 27:805-812.
136. Diabetes Prevention Program Research Group. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. N Engl J Med 2002; 346:393-403.
137. Sharif A., Moore R., Baboolal K. Influence of lifestyle modification in renal transplant recipients with postprandial hyperglycemia. Transplantation 2008, 85:353-358.
138. Knight SR, Morris PJ. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation 2010;89:1-14.
139. Hoogwerf B., Danese R.D. Drug selection and the management of corticosteroid-related diabetes mellitus. Rheum Dis Clin North Am 1999, 25:489-505.
140. Canadian Pharmacists Association, in Compendium of pharmaceuticals and specilaties. 2010.
141. McCormack J., Johns K., Tildesley H. Metformin's contraindications should be contraindicated. CMAJ 2005, 173:502-504.
142. Harrower A.D. Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency. Clin Pharmacokinet 1996, 31:111-119.
143. Turk T., Witzke O. Pharmacological interaction between cyclosporine a and repaglinide. Is it clinically relevant?. Am J Transplant 2006, 6:2223.
144. Turk T., Pietruck F., Dolff S., Kribben A., Janssen O.E., Mann K., et al. Repaglinide in the management of new-onset diabetes mellitus after renal transplantation. Am J Transplant 2006, 6:842-846.
145. Kajosaari L.I., Niemi M., Neuvonen M., Laitila J., Neuvonen P.J., Backman J.T. Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther 2005, 78:388-399.
146. Charpentier G., Riveline J.P., Varroud-Vial M. Management of drugs affecting blood glucose in diabetic patients with renal failure. Diabetes Metab 2000, 26(Suppl. 4):73-85.
147. Villanueva G., Baldwin D. Rosiglitazone therapy of posttransplant diabetes mellitus. Transplantation 2005, 80:1402-1405.
148. Luther P., Baldwin D. Pioglitazone in the management of diabetes mellitus after transplantation. Am J Transplant 2004, 4:2135-2138.
149. Grey A.B. Skeletal toxicity of thiazolidinediones. Ann Intern Med 2008, 148:563.
150. Saemann MD, Krebs M. Thiazolidinediones in the treatment of patients with Post-Transplant-Hyperglycemia or new-onset diabetes mellitus after renal transplantation (NODAT) - A new therapeutic option? Wien Klin Wochenschr 2010;122:198-202.
151. Krishna R., Bergman A., Larson P., Cote J., Lasseter K., Dilzer S., et al. Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 Inhibitor, in healthy male subjects. J Clin Pharmacol 2007, 47:165-174.
152. Ozdemir F.N., Karakan S., Akgul A., Haberal M. Metabolic syndrome is related to long-term graft function in renal transplant recipients. Transplant Proc 2009, 41:2808-2810.
153. Volgi J.R., Baldwin D. Glucocorticoid therapy and diabetes management. Nurs Clin North Am 2001, 36:333-339. [viii].
154. Gonzalez-Posada J.M., Hernandez D., Genis B.B., Tamajon L.P., Perez J.G., Maceira B., et al. Increased cardiovascular risk profile and mortality in kidney allograft recipients with post-transplant diabetes mellitus in Spain. Clin Transplant 2006, 20:650-658.
155. Gourishankar S., Jhangri G.S., Tonelli M., Wales L.H., Cockfield S.M. Development of diabetes mellitus following kidney transplantation: a Canadian experience. Am J Transplant 2004, 4:1876-1882.
156. Ollech J.E., Kramer M.R., Peled N., Ollech A., Amital A., Medalion B., et al. Post-transplant diabetes mellitus in lung transplant recipients: incidence and risk factors. Eur J Cardiothorac Surg 2008, 33:844-848.
157. Ferner R.E., Chaplin S. The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs. Clin Pharmacokinet 1987, 12:379-401.